Table 1.

Summary of data obtained in clinical trials in medulloblastoma

Ref.Trial and accrual periodTreatment (Gy, posterior fossa/craniospinal axis)5-y survival rate (%)P
Average risk
(26)HIT'91, 1991-1997Preradiation (55.2/35.2) ifosfamide, methotrexate, etoposide, cytarabine vs. postradiation (55.2/35.2) lomustine, vincristine and cisplatin65 vs. 78<0.03
(30)SIOP III, 1992-2000Preradiation (55/35) cyclophosphamide, vincristine, etoposide and carboplatin vs. radiation (55/35)74 vs. 600.036
(48)CCG9892, 1990-1994Postradiation (55.2/23.4) vincristine, lomustine and cisplatin79
(27)SJMB'96, 1996-1999Postradiation (55/23.4) high-dose cyclophosphamide, cisplatin and vincristin94
(49)POG8631/CCG923, 1986-1990Radiation (54/36) vs. radiation (54/23.4)67 vs. 520.14
High risk
(50)CCG921, 1986-1992Postradiation (54/36) vincristine, lomustine and prednisolone vs. eight drugs in 1 d preradiation and postradiation (54/36)63 vs. 430.006
(27)SJMB'96, 1996-1999Preradiation topotecan window then high-dose cyclophosphamide, cisplatin, and vincristin84
(29)Limited institution CHOP/CNMC/CMCD, 1983-1993Postradiation (55.2/36) postradiation (55.2/36) vincristin, lomustin, and cisplatin67